Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) for use by diabetics and pre-diabetics, announced the grant of U.S. Patent 10,092,224, Cumulative Measurement of an Analyte.
SugarBEAT® CGM utilizes a proprietary, daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.
The newly granted patent allows sensing to occur in sub-five-minute intervals by allowing for cumulative measurements to be taken and processed by the algorithm rather than waiting for complete depletion of glucose concentrations.
Globally, there are more than 400M diabetics and 1B pre-diabetics. The annual addressable market for CGM for diabetics (excluding pre-diabetics) is estimated at $82B, with the U.S. market estimated at $13B. CGM adoption among diabetics is growing rapidly; the U.S. market saw 117% growth in 2018.
The Backstory: Nemaura Medical Inc. is a medical technology company developing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated by a finger stick reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
To read full newsletter and learn about other top small cap stocks
